Stocks Health care ANIX
NASDAQ · Health careAnixa Biosciences Inc (ANIX)
It posted a net loss of $10.4M. At July 31, 2026 it held $1.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 9, 2026.
Key facts about Anixa Biosciences Inc
- Net worth
- Anixa Biosciences Inc has a market value (market cap) of $107.5M at the latest share price, and shareholders' equity of $14.5M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $210K (0.0% year on year), with a net loss of $12.6M.
- Cash flow
- In fiscal 2025 operations used $7.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 9, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR
- Next earnings report
- Anixa Biosciences Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Anixa Biosciences Inc does
Anixa Biosciences Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.9M | -$0.34 | n/a |
| 2024 | $210K | -$12.6M | -$0.39 | n/a |
| 2023 | $210K | -$9.8M | -$0.32 | n/a |
| 2022 | n/a | -$13.6M | $0.45 | n/a |
| 2022 | $512K | -$13M | -$0.45 | n/a |
| 2020 | n/a | -$10M | -$0.45 | -$6.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Anixa Biosciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026
- June 10, 2026
- March 11, 2026
- March 9, 2026
- February 9, 2026
- January 28, 2026Proxy statement DEF 14A
- January 12, 2026
- January 12, 2026
- January 6, 2026Activist stake changed SCHEDULE 13D/A
- December 12, 2025
Insider trades
What the people running Anixa Biosciences Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $291.6K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Kumar AmitChief Executive Officer, Director | Bought | 5,000 | $15.9K |
| October 23, 2026 | Titterton Lewis H jrDirector | Bought | 8,000 | $23.8K |
| October 22, 2026 | Kumar AmitChief Executive Officer, Director | Bought | 8,000 | $21.8K |
| September 30, 2026 | Catelani MichaelPresident, COO, & CFO | Bought | 5,500 | $15.6K |
| September 24, 2026 | Baskies Arnold MDirector | Bought | 5,000 | $13.8K |
| September 24, 2026 | Kumar AmitChief Executive Officer, Director | Bought | 7,000 | $19.5K |
| September 23, 2026 | Titterton Lewis H jrDirector | Bought | 49,036 | $131.9K |
| September 10, 2026 | Titterton Lewis H jrDirector | Bought | 10,000 | $27.3K |
Who owns ANIX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Amit Kumar13D, may seek influence | 16.3% | June 6, 2025 |
| Michael Catelani13D, may seek influence | 7% | January 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 62 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1,329,852 | +14,870 |
| UBS Group AG | 585,430 | +33,793 |
| Laird Norton Wetherby Trust Company, LLC | 578,727 | +12,400 |
| D.A. Davidson & Co. | 539,272 | 0 |
| Geode Capital Management, LLC | 359,194 | -5,537 |
| Marshall Wace, Llp | 328,332 | +155,153 |
| BlackRock, Inc. | 199,755 | +29,652 |
| Vanguard Fiduciary Trust Co | 192,356 | +1,282 |
| State Street Corp | 159,040 | 0 |
| LPL Financial LLC | 111,535 | +30,559 |
| Northern Trust Corp | 69,235 | +2,410 |
| Renaissance Technologies LLC | 59,373 | -1,800 |
| CoreCap Advisors, LLC | 52,020 | 0 |
| Bank of New York Mellon Corp | 47,442 | 0 |
| Westside Investment Management, Inc. | 43,000 | -4,000 |
| HighTower Advisors, LLC | 41,150 | -400 |
| Kestra Advisory Services, LLC | 38,000 | -13,000 |
| Corient Private Wealth LP | 37,400 | +17,400 |
| Gemmer Asset Management LLC | 35,000 | 0 |
| Modern Wealth Management, LLC | 32,000 | new |
Insiders
4 insiders reported holding 1,929,575 shares in total, about $6.1M at the last price.
| Holder | Shares |
|---|---|
| Titterton Lewis H jrDirector | 1,054,003 |
| Kumar AmitChief Executive Officer, Director | 685,000 |
| Baskies Arnold MDirector | 140,572 |
| Catelani MichaelPresident, COO, & CFO | 50,000 |
Questions about ANIX
What does Anixa Biosciences Inc do?
Anixa Biosciences Inc is a company in the Health care sector, listed on NASDAQ as ANIX. Its shares trade on NASDAQ under the ticker ANIX.
What is Anixa Biosciences Inc's net worth?
Anixa Biosciences Inc has a market value (market cap) of $107.5M at the latest share price, and shareholders' equity of $14.5M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Anixa Biosciences Inc profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $10.4M.
When did Anixa Biosciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 9, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the insider trade from November 2, 2026.
When is Anixa Biosciences Inc's next earnings report?
Anixa Biosciences Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANIX with
Follow ANIX
Get an email when Anixa Biosciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Anixa Biosciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.